middle.news
Neuren Secures FDA Nod on Phase 3 Endpoints for PMS Drug NNZ-2591
2:39am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Neuren Secures FDA Nod on Phase 3 Endpoints for PMS Drug NNZ-2591
2:39am on Monday 2nd of June, 2025 AEST
Key Points
FDA confirms co-primary endpoints for NNZ-2591 Phase 3 trial
Endpoints focus on VABS-3 Receptive Communication and PMSA-C scores
Phase 2 results showed clinically meaningful improvements in 16 of 18 children
Phase 3 trial expected to start mid-2025, no additional funding needed
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE